Ilumetri

tildrakizumab · Almirall, S.A.
AUTHORISED IN THE EU

What Ilumetri is used for

Ilumetri is indicated for the treatment of adults with moderate to severe plaque psoriasis who are candidates for systemic therapy.

Approved use, as published by the European Medicines Agency.

Key facts

Brand
Ilumetri
Active substance
tildrakizumab
Disease area
Psoriasis
Medicine group
Immunosuppressants;Interleukin inhibitors
ATC code
L04AC
Marketing authorisation holder
Almirall, S.A.
Authorised in the EU since
2018

Official information

In the USA

Same active substance: Ilumya

Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.

Common questions

What is Ilumetri used for?

Ilumetri is indicated for the treatment of adults with moderate to severe plaque psoriasis who are candidates for systemic therapy.

What is the active substance in Ilumetri?

Ilumetri contains tildrakizumab.

Who makes Ilumetri?

The EU marketing authorisation holder is Almirall, S.A..

Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.

← All specialty medicines, EU

For information only, not medical advice. This page is a plain-language summary written from standard prescribing information and the public guides linked below. Brands sometimes change their formula, so always check the composition printed on the pack. Doses here are typical adult doses; yours may differ. Do not start, stop or change a medicine without your doctor or pharmacist, and keep all medicines away from children. In an emergency, call 112 (India) or your local emergency number.